Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Neoadjuvant cisplatin-based chemotherapy (NAC) followed by radical cystectomy and pelvic lymph node dissection is the optimal treatment for patients with muscle-invasive bladder cancer. In recent years, the VESPER trial showed a statistically significant higher progression-free survival with dd-MVAC...

Full description

Bibliographic Details
Main Authors: Stéphane Culine, Valentin Harter, Clémentine Krucker, Gwenaelle Gravis, Aude Fléchon, Christine Chevreau, Hakim Mahammedi, Brigitte Laguerre, Aline Guillot, Florence Joly, Jacqueline Fontugne, Yves Allory, Christian Pfister
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Cancers
Subjects:
muscle-invasive bladder cancer
cisplatin-based chemotherapy
neoadjuvant treatment
pathological complete response
Online Access:https://www.mdpi.com/2072-6694/15/6/1742

Internet

https://www.mdpi.com/2072-6694/15/6/1742

Similar Items